The occurrence of grade @-@ infusion reactions was lower with panitumumab than with cetuximab ( one -LSB- < @ % -RSB- patient vs nine -LSB- @ % -RSB- patients ) , and the occurrence of grade @-@ hypomagnesaemia was higher in the panitumumab group ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .